Enrique Poradosu, Chief Science & Business Officer at Nuvectis Pharma, Inc. (NVCT), bought 4,600 shares at $3.88 ($16K) on 2022-02-07, disclosed to the SEC on 2022-02-08.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $3.35 | 3,800 | $13K | 80.4% |
| 2 | $3.88 | 800 | $3K | 19.6% |
| Total | $3.44 avg | 4,600 | $16K | 100% |
| Filing → |
| NVCT | BUY | 2023-03-28 | $6K | — | Filing → |
| NVCT | BUY | 2022-05-16 | $10K | — | Filing → |